Condition: Oligometastatic Prostate Cancer (OMPC) · Sponsor: Novartis Pharmaceuticals
The purpose of this study is to evaluate the efficacy and safety of lutetium (177Lu) vipivotide tetraxetan (AAA617) in participants with oligometastatic prostate cancer (OMPC) progressing after definitive therapy to their primary tumor. The data generated from this study will provide evidence for the treatment of AAA617 in early-stage prostate cancer patients to control recurrent tumor from progressing to fatal metastatic disease while preserving quality of life by delaying treatment with androgen deprivation therapy (ADT).
This description comes directly from the study's public registry record.
Novartis Pharmaceuticals · 1-888-669-6682 · novartis.email@novartis.com
Novartis Pharmaceuticals · +41613241111 · novartis.email@novartis.com
Always discuss trial participation with your own doctor first.
| Highlands Oncology Group | Fayetteville, Arkansas, United States | Recruiting |
| VA Greater LA Healthcare System | Los Angeles, California, United States | Recruiting |
| VA Palo Alto Health Care System | Palo Alto, California, United States | Recruiting |
| Stanford University | Palo Alto, California, United States | Recruiting |
| UCSF | San Francisco, California, United States | Recruiting |
| Rocky Mountain Cancer Centers | Denver, Colorado, United States | Recruiting |
| Cancer Specialists of North Florida | Jacksonville, Florida, United States | Recruiting |
| Woodlands Medical Specialists | Pensacola, Florida, United States | Recruiting |
| Piedmont Healthcare | Atlanta, Georgia, United States | Recruiting |
| University of Chicago | Chicago, Illinois, United States | Recruiting |
| The Cancer Institute of Alexian Brothers | Elk Grove, Illinois, United States | Recruiting |
| Unity Point Clinic | Des Moines, Iowa, United States | Recruiting |
+ 135 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05939414